Nurix Therapeutics, Inc. (NASDAQ:NRIX) Q1 2026 Earnings and Pipeline Update
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Q1 2026 Earnings and Pipeline Update
Key Highlights:
- EPS Miss and Revenue Shortfall: Nurix reported an EPS of -$0.79, missing consensus estimates of approximately -$0.76 to -$0.78. Revenue came in at $6.3 million, well below expectations of around $14.25 million.
- Strong Cash Position Amid Losses: The company ended the quarter with $540.7 million in cash, cash equivalents, and marketable securities, providing a solid runway. It reported a net loss of $87.2 million.
- Pipeline Progress: Nurix continues to advance its clinical programs, including the ongoing pivotal Phase 2 DAYBreak CLL-201 trial of bexobrutideg (NX-5948) in relapsed/refractory chronic lymphocytic leukemia (CLL), with plans to initiate a confirmatory Phase 3 trial. The company also targets a 2026 IND submission for bexobrutideg in inflammatory and autoimmune indications and is progressing partnered programs for IRAK4 (Phase 1) and STAT6 (IND-enabling).
Nurix Therapeutics, Inc. (NASDAQ:NRIX) is a clinical-stage biopharmaceutical company focused on developing targeted protein degraders for the treatment of cancer and inflammatory/autoimmune diseases. It operates in the biotechnology sector, with a particular emphasis on the Zacks Medical - Biomedical and Genetics industry group.
On April 8, 2026, Nurix reported financial results for the fiscal first quarter ended February 28, 2026. The company posted an EPS of -$0.79, missing estimates (surprise of roughly -4.22%). This compares to an EPS of -$0.67 in the year-ago quarter. Over the past year, Nurix has beaten EPS estimates in only a limited number of quarters.
Revenue totaled $6.3 million, significantly below consensus estimates (shortfall of approximately 57%). This represents a sharp decline from $18.5 million in the same quarter last year, primarily due to the completion of the initial research term for certain targets under the Sanofi collaboration. Nurix has a mixed track record of beating revenue estimates in recent quarters.
Financially, Nurix remains well-capitalized with $540.7 million in cash, cash equivalents, and marketable securities as of February 28, 2026 (down from $592.9 million at the end of the prior quarter). The company reported a net loss of $87.2 million. Operating expenses rose, driven by higher R&D investment (approximately $84.1 million) as the company accelerates clinical programs, along with increased G&A costs (approximately $14.6 million). Note that collaboration-heavy biotechs like Nurix can show negative gross margins in reporting due to the classification of certain costs against collaboration revenue.
Market news and analyst rating coverage
Rayan Ahmad covers market news, analyst rating changes, and company developments for the FMP blog. His work focuses on summarizing price-target updates, earnings results, and broker actions into accessible, data-backed market updates.
Financial data for every need
Real-time quotes and 30+ years of historical data, including prices, fundamentals, and insider transactions — all accessible via API.
Create Free Account